CTRI Number |
CTRI/2018/04/013462 [Registered on: 24/04/2018] Trial Registered Retrospectively |
Last Modified On: |
13/04/2018 |
Post Graduate Thesis |
Yes |
Type of Trial |
Interventional |
Type of Study
|
Drug |
Study Design |
Randomized, Parallel Group, Placebo Controlled Trial |
Public Title of Study
|
Study to compare the effect of a medicine (lignocaine) given by two ways,first one is by vapour
(nebulisation)and second by injection into the blood to reduce the blood pressure and heart rate changes during the procedure of passing the tube into the wind pipe(trachea) tube to wind pipe |
Scientific Title of Study
|
Comparison between intravenous and nebulised lignocaine for haemodynamic response to laryngoscopy and intubation |
Trial Acronym |
|
Secondary IDs if Any
|
Secondary ID |
Identifier |
NIL |
NIL |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Kiran R Asranna |
Designation |
junior resident |
Affiliation |
KMC Manipal |
Address |
Department of Anaesthesiology
CSOT Block
Kasturba Hospital
Manipal University
Manipal Room no. 423,
NBQ Hostel,
KMC campus,
Manipal Udupi KARNATAKA 576104 India |
Phone |
9986373248 |
Fax |
|
Email |
kirz92cool@gmail.com |
|
Details of Contact Person Scientific Query
|
Name |
Kiran R Asranna |
Designation |
Junior Resident |
Affiliation |
KMC Manipal |
Address |
Department of Anaesthesiology
CSOT Block
Kasturba Hospital
Manipal University
Manipal Room no. 423
NBQ Hostel
KMC Campus,
Manipal Udupi KARNATAKA 576104 India |
Phone |
9986373248 |
Fax |
|
Email |
kirz92cool@gmail.com |
|
Details of Contact Person Public Query
|
Name |
Shaji Mathew |
Designation |
Associate Professor |
Affiliation |
KMC Manipal |
Address |
Department of anaesthesiology
CSOT Block
Kasturba Hospital
Manipal University
Manipal NBQ hostel,
Kmc campus,
Manipal Udupi KARNATAKA 576104 India |
Phone |
9964620729 |
Fax |
|
Email |
shajimanipal@yahoo.co.in |
|
Source of Monetary or Material Support
|
Manipal Academy of Higher Education, Kasturba College and Hospital, Manipal, Udupi,
Karnataka
|
|
Primary Sponsor
|
Name |
Kasturba Medical College PG thesis fund |
Address |
Kasturba medical college,
Manipal Academy of Higher Education,Manipal,Udupi,Karnataka |
Type of Sponsor |
Private medical college |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 1 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr Kiran R |
Kasturba Medical College and Hospital,Manipal |
Department of Anesthesia
Manipal Academy of Higher Education, Kasturba College and Hospital, Manipal. Udupi KARNATAKA |
9986373248
kirz92cool@gmail.com |
|
Details of Ethics Committee
|
No of Ethics Committees= 1 |
Name of Committee |
Approval Status |
KASTURBA MEDICAL COLLEGE AND KASTURBA HOSPITAL-INSTITUTIONAL ETHICS COMMITTEE |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
|
Health Type |
Condition |
Patients |
Age group between 18 and 65years of either
gender belonging to ASAPS 1 undergoing any surgery under general anaesthesia with endotracheal intubation., |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Comparator Agent |
Group C |
Control group |
Intervention |
Group I |
Group I receives 1.5 mg/kg of preservative free 2% lignocaine intravenously 90 seconds before laryngoscopy |
Intervention |
Group N |
Group N receives 5ml of 4% Nebulised lignocaine 15 to 20 minutes before laryngoscopy |
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
60.00 Year(s) |
Gender |
Both |
Details |
Elective surgical procedures under general anaesthesia requiring endotracheal intubation
Age between 18 to 60 years age of either gender
Modified Mallampati class I & II
ASA PS I
|
|
ExclusionCriteria |
Details |
1. Anticipated difficult airway
2. Baseline heart rate < 50 bpm
3. At risk for gastric aspiration
4. BMI > 30 kg/m2
5. Known allergy to lignocaine
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
Blinding/Masking
|
Participant Blinded |
Primary Outcome
|
Outcome |
TimePoints |
hemodynamic response
1)Heart rate
2)Mean arterial pressure |
1- Baseline value
2- Just before laryngoscopy
3- Immediately after laryngoscopy and intubation
4- Every minute after laryngoscopy and intubation for the first 5 minutes
|
|
Secondary Outcome
|
Outcome |
TimePoints |
Duration of laryngoscopy |
Should not exceed 15 seconds |
|
Target Sample Size
|
Total Sample Size="66" Sample Size from India="66"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
Phase of Trial
|
Phase 2/ Phase 3 |
Date of First Enrollment (India)
|
20/02/2017 |
Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
Date of First Enrollment (Global) |
Date Missing |
Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
Recruitment Status of Trial (Global)
|
Not Applicable |
Recruitment Status of Trial (India) |
Open to Recruitment |
Publication Details
|
Not published |
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
|
Brief Summary
|
Several studies have been made in order to attenuate these
haemodynamic response to laryngoscopy and intubation. Many drugs also have been
used for the same purpose [3]. The techniques include topical anaesthesia of
oropharynx (viscous lignocaine) laryngotracheal instillation of lignocaine just
prior to intubation, intravenous lignocaine, adrenergic blocking drugs, (either
alpha or beta blockers) vasodilators like hydrallazine, sodium nitroprusside,
nitroglycerine, deep inhalational anaesthesia, intravenous opioids etc., No
single agent has been established as the most Anaesthesia Section appropriate
for this purpose. Among the recommended procedures, intravenous lidocaine or
fentanyl appear to best fulfill the above mentioned criteria [2]. Lignocaine is
a amide (-NHCO-) synthetic local anaesthetic. The use of lignocaine is well
known in treatment of patients with ventricular dysarrthmias and as prophylaxis
in treatment of ventricular tachyarrthmias especially in connection with
myocardial infarction and mechanical irritation of cardia. The principal
metabolic pathway of lignocaine is oxidative dealkalysation in the liver to
monoethylglylcinexylidide followed by hydrolysis of this metabolite to xylidide.
Monoethylglycinexylidide has approximately 80% of the activity of lignocaine
for protection against cardiac dysarrythmias. Lignocaine prevents transmission
of nerve impulse (conduction blockade) by inhibiting passage of sodium ions
through ion selective sodium channels in nerve membrane [4]. The sodium channel
itself is a specific receptor to lignocaine molecule. Fentanyl is a potent,
synthetic narcotic analgesic with a rapid onset and short duration of action.
It is extremely lipid soluble, has a low molecular weight and is a synthetic
opioid agonist which is popularly used as intravenous analgesic supplement,
component of inhalation anaesthesia, balanced anaesthesia and neurolept
analgesia and also as a sole anaesthetic. It is 75 to 125 times more potent
than morphine as an analgesic [5]. After intravenous administration, onset of
effect is 1-2 minutes, and the duration is 1 hour. Consequently it has proved
ideal for control of the short lived haemodynamic sequelae, associated with
laryngoscopy and intubation.
Some studies note a response of intravenous lignocaine in
blunt-ing rises in pulse, blood pressure, intracranial and intraocular
pressure. Studies have discussed the possible mechanisms to account for these
observations with IV lignocaine. These include a direct myocardial depressant
effect, a peripheral vasodilating effect and finally an effect on synaptic
transmission [8]. A review on “Prophylactic lidocaine use preintubationâ€. They
said that a dose of prophylactic lidocaine of 1.5 mg/kg given intravenously 3
minutes before intubation is optimal. No studies document any harmful effects
of prophylactic lidocaine given preintubation [15]. Wang et al., [16] reported
most optimal time of administration of intravenous lidocaine to attenuate the
increase of intraocular pressure seemed to be the space between 1-3 minutes
before laryngoscopy and tracheal intubation. Wilson et al., [17] showed that
irrespective of the timing of administration of injection of lignocaine 2, 3 or
4 minutes before tracheal intubation, there was a significant increase in heart
rate of 21-26% in all groups. There was no significant increase in mean artrial
pressure (MAP) in response to intubation in any group of patients given
lignocaine before intubation, but in the placebo group, MAP increased by 19%
compared to baseline values. Mollick et al., [18] observed that intravenous
lignocaine with pethidine did attenuate the sympathetic responses to
laryngoscopy and endotracheal intubation which came down to base line before 5
minute after intubation. But the group of patients which was treated only with
lignocaine, their sympathetic responses did not come down to base line at 5
minute after laryngoscopy and endotracheal intubation. Similar to our
observation Bachofen M [2] too reported that fentanyl showed a significant
pressure-lowering action persisting over the whole observation period in all
patients while no significant effect of lidocaine on the pressure response
could be observed. Malde and Sarode [19] concluded that “ given 5 minutes prior
to intubation, lignocaine (1.5 mg/kg) and fentanyl (2 µg/kg) both attenuated
the rise in pulse rate, though fentanyl was better. |